Last reviewed · How we verify
Febuxostat 40 mg
At a glance
| Generic name | Febuxostat 40 mg |
|---|---|
| Also known as | Feburic |
| Sponsor | Ardea Biosciences, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Time Required to Dissolve Urate Deposits
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia (PHASE2)
- Effect of Dotinurad in Hyperuricemia With Hypertension (PHASE4)
- Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects (PHASE1)
- A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout (PHASE3)
- Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness (PHASE1)
- The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More (PHASE4)
- Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Febuxostat 40 mg CI brief — competitive landscape report
- Febuxostat 40 mg updates RSS · CI watch RSS
- Ardea Biosciences, Inc. portfolio CI